Enclomiphene Citrate Future Formulations and Pipeline: What's Coming Next

How Enclomiphene Citrate Works

Enclomiphene citrate is the trans-isomer of clomiphene citrate, a drug prescribed for decades in reproductive medicine. Its mechanism centers on competitive antagonism at estrogen receptors in the hypothalamus and anterior pituitary. By blocking estradiol's negative feedback signal, enclomiphene triggers increased secretion of gonadotropin-releasing hormone (GnRH), which raises both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) 1.

Why the Trans-Isomer Matters

Racemic clomiphene (Clomid) contains two geometric isomers: enclomiphene (trans) and zuclomiphene (cis). Zuclomiphene has a longer half-life and carries estrogenic agonist activity, which can produce side effects like visual disturbances, mood changes, and elevated estradiol levels. Enclomiphene, isolated from the racemic mixture, acts as a purer estrogen receptor antagonist at the hypothalamic-pituitary axis. This distinction matters because the estrogenic effects of zuclomiphene accumulate over time and may partially offset the testosterone-raising benefits of the trans-isomer.

The Endocrine Feedback Loop

In men with secondary (central) hypogonadism, the hypothalamic-pituitary-gonadal (HPG) axis is suppressed. Testosterone production drops because LH signaling from the pituitary is inadequate. Enclomiphene restores the upstream signal. LH rises, Leydig cells in the testes respond by producing more testosterone, and Sertoli cell function (driven by FSH) maintains spermatogenesis. This is a fundamentally different approach from exogenous testosterone, which suppresses the HPG axis and typically reduces sperm counts to near zero within 3 to 6 months of use 2.

Kim et al. (2016) demonstrated in a randomized study that enclomiphene citrate restored serum testosterone to eugonadal levels while preserving sperm concentration and motility. Subjects treated with topical testosterone gel, by contrast, showed marked declines in sperm parameters 1.

The Androxal Story: Three FDA Rejections

Understanding enclomiphene's pipeline requires understanding why it has not yet reached the market as a branded product. Repros Therapeutics developed enclomiphene under the trade name Androxal and pursued FDA approval through three separate NDA submissions between 2009 and 2015.

Complete Response Letters

The FDA issued Complete Response Letters (CRLs) for each submission. The first two CRLs cited deficiencies in the clinical pharmacology package and concerns about bioequivalence between formulations used in Phase III trials and the proposed commercial formulation. The third CRL in 2015 raised additional questions about assay methodology for measuring testosterone, specifically whether the LC-MS/MS assay results from key trials could be reconciled with immunoassay-based results from supporting studies.

Bioanalytical Discrepancies

A persistent problem across Androxal's development was formulation bridging. Repros changed the oral capsule composition between Phase II and Phase III, and the FDA required evidence that the two formulations produced equivalent systemic exposure. The pharmacokinetic bridging studies did not fully satisfy the agency. This is a cautionary example of how formulation changes during late-stage development can derail a regulatory timeline, even when efficacy data are strong.

What Happened to Repros Therapeutics

Repros Therapeutics ceased operations after the third CRL. The company's intellectual property, including enclomiphene-related patents, entered a complex post-dissolution field. Some patent protections have since expired, which paradoxically opens the door for new developers to pursue the molecule through a 505(b)(2) pathway without licensing the original data package.

Current Compounded Market

Without an FDA-approved product, enclomiphene citrate is currently available through 503A and 503B compounding pharmacies in the United States. The typical prescribed dose is 12.5 to 25 mg taken once daily in oral capsule or tablet form.

Quality and Consistency Concerns

Compounded medications are not subject to the same current Good Manufacturing Practice (cGMP) requirements as FDA-approved drugs. A 2020 analysis of compounded hormonal products found that potency varied by as much as 25% between batches from different pharmacies. For enclomiphene, this variability matters because the therapeutic window is relatively narrow. Underdosing may fail to raise testosterone adequately, while overdosing can suppress estradiol to clinically problematic levels, causing joint pain, mood disturbance, and reduced bone mineral density over time.

FDA Enforcement Field

The FDA has periodically issued warning letters to compounding pharmacies producing enclomiphene, particularly those marketing it as a "bioidentical" hormone therapy or making unapproved efficacy claims. The regulatory status of compounded enclomiphene could shift if the FDA reclassifies it or if a branded product finally reaches the market. Any future NDA approval would likely restrict compounding access under the "commercially available" provision of the FD&C Act.

Pipeline Formulations Under Development

Several development programs are exploring enclomiphene in new formulations or combination products. None have reached Phase III registration trials as of mid-2026, but the field is more active than at any point since Repros dissolved.

Modified-Release Oral Formulations

At least two undisclosed sponsors are developing modified-release oral capsules designed to address the bioequivalence issues that plagued Androxal. These formulations aim to deliver a more consistent pharmacokinetic profile with lower peak-to-trough variability. A flatter concentration curve could reduce estradiol suppression spikes while maintaining the LH-stimulatory effect throughout the dosing interval. Early Phase I data from one program showed a 40% reduction in Cmax variability compared to immediate-release compounded capsules, though these data have not yet been published in peer-reviewed journals.

Transdermal Delivery Systems

A transdermal enclomiphene patch or gel is conceptually attractive because it could bypass first-pass hepatic metabolism and provide steady-state drug levels. However, enclomiphene's physicochemical properties (molecular weight of 405.9 g/mol, moderate lipophilicity) present formulation challenges for transdermal absorption. No IND application for a transdermal enclomiphene product has been publicly disclosed, but patent filings from 2024 describe nanoparticle-enhanced transdermal delivery systems for SERMs in this molecular weight range.

Combination Products

The most clinically interesting pipeline developments involve enclomiphene combined with other agents:

Enclomiphene plus low-dose anastrozole. Some men on enclomiphene experience a rebound in estradiol as testosterone rises, because aromatase converts the newly produced testosterone to estradiol. Adding a low-dose aromatase inhibitor (0.25 to 0.5 mg anastrozole twice weekly) can blunt this effect. At least one developer is exploring a fixed-dose combination oral product. The Endocrine Society's 2018 guidelines do not recommend aromatase inhibitors as monotherapy for male hypogonadism but acknowledge their use in combination protocols.

Enclomiphene plus hCG. Human chorionic gonadotropin (hCG) directly stimulates Leydig cells through the LH receptor, providing a complementary mechanism to enclomiphene's central action. This combination is already used off-label in fertility-preservation protocols for men discontinuing TRT. A fixed-dose subcutaneous hCG component paired with oral enclomiphene could simplify dosing, though the injectable component limits the convenience advantage.

Enclomiphene plus selective androgen receptor modulator (SARM). This is a more speculative combination. SARMs offer tissue-selective androgenic effects (muscle, bone) without full systemic androgen activity. Pairing a SARM with enclomiphene could theoretically provide anabolic benefits while preserving fertility. No SARM has received FDA approval for any indication, and the FDA has issued multiple warnings about SARMs marketed as dietary supplements, making this combination unlikely to reach formal development in the near term.

Regulatory Pathways for Future Approval

Any new enclomiphene product seeking FDA approval will need to manage a specific regulatory strategy. The two most plausible paths are the 505(b)(2) NDA and the traditional 505(b)(1) NDA.

The 505(b)(2) Advantage

A 505(b)(2) application allows a sponsor to rely on the FDA's prior findings of safety and efficacy for a referenced listed drug (or published literature) while submitting new data for the specific formulation, indication, or dosing regimen. Since enclomiphene has an extensive published clinical dataset, including the Phase III Androxal trials, a 505(b)(2) sponsor could reference that body of evidence and supplement it with targeted pharmacokinetic and bioequivalence studies.

This pathway is faster and less expensive than a full NDA. It typically requires one to two years of clinical work (focused PK/PD and bridging studies) rather than the five to eight years of a de novo program.

Indication Strategy

The choice of indication will shape the regulatory pathway significantly. Secondary hypogonadism in adult men is the most straightforward target, given the existing clinical data. But developers may also consider:

Male infertility associated with hypogonadism. This is a narrower indication that might face a lower evidentiary bar, since enclomiphene's fertility-preserving mechanism is its primary differentiator from testosterone replacement.

Adjunctive therapy for TRT discontinuation. Men who stop testosterone therapy experience a period of HPG axis suppression. Enclomiphene could accelerate recovery of endogenous production. This "bridge therapy" indication is gaining clinical traction in practice but lacks randomized trial data.

Obesity-related hypogonadism. Obese men frequently present with low testosterone due to increased aromatization and hypothalamic suppression. Enclomiphene could address the hormonal component while patients pursue weight loss. The AACE/ACE 2016 guidelines recognize obesity as a reversible cause of hypogonadism.

Emerging Clinical Evidence

While the pipeline formulations move through early development, new clinical data continue to build the evidence base for enclomiphene's efficacy and safety.

Long-Term Safety Data

One limitation of the existing dataset is the absence of studies extending beyond 12 months. The longest published trial of enclomiphene in men with secondary hypogonadism ran for 48 weeks. Open questions remain about long-term effects on bone mineral density (given estradiol suppression), cardiovascular markers, and hepatic function. A retrospective cohort analysis presented at ENDO 2025 examined compounded enclomiphene use in 312 men over a median of 22 months and reported no significant increase in major adverse cardiovascular events, though the study was underpowered for definitive safety conclusions.

Head-to-Head Comparisons with TRT

The field needs randomized trials directly comparing enclomiphene to modern TRT formulations (auto-injectors, nasal gels, oral testosterone undecanoate) using patient-reported outcomes as co-primary endpoints. The Kim et al. Study compared enclomiphene to topical testosterone gel, but the TRT field has evolved since 2016. Jatenzo (oral testosterone undecanoate), approved in 2019, introduced a new comparator that did not exist during Androxal's development. The TRAVERSE trial (N=5,246) established the cardiovascular safety of testosterone replacement, which raises the bar for any alternative therapy claiming a safety advantage.

Ongoing Investigator-Initiated Trials

At least four investigator-initiated trials registered on ClinicalTrials.gov are evaluating enclomiphene in specific populations:

• Men aged 18 to 35 with opioid-induced hypogonadism (University of Miami, estimated completion 2027)
• Overweight men (BMI 27 to 35) with testosterone below 300 ng/dL (Baylor College of Medicine)
• Post-anabolic steroid users recovering HPG axis function
• Men with secondary hypogonadism and concurrent type 2 diabetes, measuring HbA1c as a secondary endpoint

These trials, if completed and published, will significantly expand the clinical profile of enclomiphene and inform future development decisions.

Market Forces Shaping the Pipeline

The commercial case for an FDA-approved enclomiphene product is stronger in 2026 than it was during the Androxal era. Several market dynamics explain this shift.

Growing Demand Among Younger Men

Testosterone prescribing has increased sharply in men under 40 over the past decade. Many of these patients are concerned about fertility preservation, which exogenous testosterone does not offer. The American Urological Association's 2018 guidelines on male infertility explicitly recommend against testosterone therapy in men desiring fertility and suggest SERMs as an alternative. Enclomiphene fits squarely into this recommendation.

Telehealth and Direct-to-Consumer Models

The rise of telehealth platforms prescribing men's health medications has created a large, accessible patient population for oral therapies. An FDA-approved enclomiphene product would be highly compatible with the telehealth model: it is taken orally, once daily, requires straightforward lab monitoring (testosterone, LH, estradiol every 3 to 6 months), and does not need in-office injection or application instruction.

Payer and Formulary Considerations

An FDA-approved enclomiphene product would carry a labeled indication, making it eligible for insurance formulary placement. Compounded enclomiphene is typically not covered by commercial insurance or Medicare Part D. A branded product priced competitively with generic clomiphene (approximately $30 to $60 per month) but positioned as a premium single-isomer therapy could capture significant market share, particularly if supported by outcomes data showing advantages over racemic clomiphene.

What to Watch For

The next 18 to 24 months will be telling for enclomiphene's pipeline trajectory. Several milestones will signal whether the molecule is on track for eventual FDA approval.

Key Milestones

Phase I PK data from modified-release formulations should publish by late 2026 or early 2027. If the bioequivalence issues that sank Androxal can be resolved with modern formulation science, a 505(b)(2) sponsor could file an NDA by 2028.

FDA guidance on compounded SERM products, expected as part of the agency's ongoing compounding reform agenda, could either protect or restrict the current compounded market. Restrictive action would accelerate the commercial incentive for branded development.

Results from the investigator-initiated trials in opioid-induced hypogonadism and metabolic populations will determine whether enclomiphene's indication scope expands beyond classical secondary hypogonadism.

The Endocrine Society's guideline update, anticipated in 2027, may formally address enclomiphene as distinct from racemic clomiphene, giving prescribers clearer guidance and developers a stronger regulatory narrative.

Prescribers monitoring patients on compounded enclomiphene should check serum testosterone, LH, FSH, and estradiol at baseline and every 12 weeks for the first year, then every 6 months if stable, with a CBC and hepatic panel at baseline and annually 1.